65,437 trials
Rheumatoid Arthritis (RA)
Primary: Safe Usability of the VIBEX MTX Device for Subcutaneous (SC) Self-injection With Methotrexate (MTX) in Adult Patients With Rheumatoid Arthritis (RA) as Demonstrated by…
SYSTEMIC SCLERODERMA
Primary: Time to Treatment Failure — 0; 8 participants
Prostate Neoplasms · Prostate Cancer
Primary: Number of Participants With Grade 3 or Higher Adverse Events (AEs) of Special Interest or Grade 3 or Higher Serious AEs Due to Study Medication — 0; 0 Participants
Squamous Cell Cancer
Primary: Progression-free Survival (PFS) Time: Investigator Read — 6.4; 5.6; 5.7 months — p=0.885
Rheumatoid Arthritis
Primary: Change From Baseline in DAS28-CRP at 12 Weeks — -1.147; -0.813; -1.237; -0.907 units on a scale
Myopia
Primary: Comfort Throughout the Day - Test Lens vs. Air Optix Aqua Lens — 74.3; 79.4 units on a scale
Brain and Central Nervous System Tumors
Primary: Median Overall Survival Time — 16.6; 14.9 months — p=0.63
Hepatitis C
Primary: Viral Load: Incidence of Sustained Virologic Response (SVR) — 4; 7; 2; 4 participants
Pertussis · Tetanus · Diphtheria
Primary: Percentage of Participants With Seroprotection Against Tetanus and Diphtheria Before and After Revaccination With ADACEL® 10 Years After a Previous Dose — 45; 49; 100…
Multiple Myeloma
Primary: Progression-free Survival (PFS) - Primary Analysis — 15.7; 8.0 weeks — p=<0.001
Healthy Volunteers
Primary: Inter-rater Reliability Using a Masseter Muscle Prominence Scale (MMPS) — 0.728; 0.711 Kendall's W
Coronary Artery Disease
Primary: P2Y12 Reaction Units — 95.0; 49.0 PRU (P2Y12 Reaction Units)
Myopia
Primary: Visual Acuity (Investigational vs Air Optix Aqua Lens) — -0.050; -0.060; -0.034; -0.039 LogMAR
Chronic Obstructive Pulmonary Disease (COPD)
Primary: St. George's Respiratory Questionnaire (SGRQ-C) Total Score After 26 Weeks of Treatment (Non-inferiority Analysis). — 44.70; 45.68; 41.30; 43.19 Score on a scale
Healthy
Primary: Skin Irritation Score of the Application Site — 0.237; 0.289; 0.250 Scores on a scale